Anticancer effect of a pyrrole‐imidazole polyamide‐triphenylphosphonium conjugate selectively targeting a common mitochondrial <scp>DNA</scp> cancer risk variant in cervical cancer cells

DOI Web Site Web Site 参考文献49件
  • Jihang Yao
    Division of Cancer Genetics Chiba Cancer Center Research Institute Chiba Japan
  • Keizo Takenaga
    Division of Cancer Genetics Chiba Cancer Center Research Institute Chiba Japan
  • Nobuko Koshikawa
    Division of Cancer Genetics Chiba Cancer Center Research Institute Chiba Japan
  • Yuki Kida
    Division of Cancer Genetics Chiba Cancer Center Research Institute Chiba Japan
  • Jason Lin
    Division of Cancer Genetics Chiba Cancer Center Research Institute Chiba Japan
  • Takayoshi Watanabe
    Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute Chiba Japan
  • Yoshiaki Maru
    Department of Molecular Carcinogenesis Chiba Cancer Center Research Institute Chiba Japan
  • Yoshitaka Hippo
    Department of Molecular Carcinogenesis Chiba Cancer Center Research Institute Chiba Japan
  • Seigi Yamamoto
    Division of Cancer Genetics Chiba Cancer Center Research Institute Chiba Japan
  • Yuyan Zhu
    Department of Urology The First Hospital of China Medical University Shenyang China
  • Hiroki Nagase
    Division of Cancer Genetics Chiba Cancer Center Research Institute Chiba Japan

抄録

<jats:title>Abstract</jats:title><jats:p>Cervical cancer remains a major threat to women's health, especially in countries with limited medical resources, and new drugs are needed to improve patient survival and minimize adverse effects. Here, we examine the effects of a triphenylphosphonium (TPP)‐conjugated pyrrole‐imidazole polyamide (CCC‐h1005) targeting the common homoplasmic mitochondrial DNA (mtDNA) cancer risk variant (ATP6 8860A>G) on the survival of cervical cancer cell lines, cisplatin‐resistant HeLa cells and patient‐derived cervical clear cell carcinoma cells as models of cervical cancer treatment. We found that CCC‐h1005 induced death in these cells and suppressed the growth of xenografted HeLa tumors with no severe adverse effects. These results suggest that PIP‐TPP designed to target mtDNA cancer risk variants can be used to treat many cervical cancers harboring high copies of the target variant, providing a foundation for clinical trials of this class of molecules for treating cervical cancer and other types of cancers.</jats:p>

収録刊行物

参考文献 (49)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ